Renji hospital shanghai jiao tong university school of medicine

Shanghai, Shanghai Municipality 200127

8 studies enrolling now · 13 studies all time

What they study most

Atherosclerosis, Chronic Lymphocytic Leukemia, Colorectal Cancer, Coronary Artery Disease, Crohn's Disease, Dermatomyositis, Gastric Cancer, IgA Nephropathy, IgG4 Related Disease, Immunoglobulin A Nephropathy, Locally Advanced Unresectable or Metastatic Solid Tumors, Locally Advanced or Metastatic Solid Tumors

Studies at this site

• A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma — Recruiting now
• A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis — Recruiting now
• A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors — Recruiting now
• A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease — Recruiting now
• A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD) — Recruiting now
• A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies — Recruiting now
• A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors — Recruiting now
• A Study of Obexelimab in Patients With Systemic Lupus Erythematosus — Recruiting now
• A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer — Running, not enrolling
• Atrasentan in Patients With IgA Nephropathy — Running, not enrolling
• A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis — Running, not enrolling
• A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease — Running, not enrolling
• A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative Colitis — Status unconfirmed